VolitionRx Launches rNuQ Webshop Following 86% Nu.Q Discover Revenue Surge
VolitionRx launched the rNuQ webshop offering ready-to-use recombinant nucleosomes manufactured in an ISO 13485 facility and shipped at +4°C in glycerol-free buffer. The company served about 100 clients, delivered 86% revenue growth for Nu.Q Discover in 2025 and anticipates similar growth in 2026 to broaden its commercialization revenue.
1. Webshop Launch and Product Offering
VolitionRx has opened its rNuQ webshop to sell off-the-shelf recombinant nucleosomes developed over the past decade. Customers can now browse, click and buy a range of configurations directly through the online portal as part of the company's shift towards commercialization.
2. Manufacturing Quality and Handling
All recombinant nucleosomes are produced in an ISO 13485 certified facility and stored and shipped at +4°C in a glycerol-free buffer. This approach ensures reproducibility, preserves structural integrity, and simplifies handling compared to traditional chromatin reagents.
3. Client Adoption and Revenue Growth
The Nu.Q Discover division serves nearly 100 clients worldwide, including top pharmaceutical and diagnostic firms. In 2025, this pillar delivered 86% revenue growth, and management expects a comparable trajectory in 2026.
4. Future Partnerships and Commercialization Outlook
VolitionRx is in discussions with several pharmaceutical companies to develop bespoke assays for various biospecimens. The rNuQ webshop is positioned to become a new revenue stream and support the commercialization of the company’s extensive epigenetics IP portfolio.